Ultrahuman raises $70m to expand health wearable and biomarker platform
The Indian health-tech brand has raised $70 million from investors including Qualcomm Ventures and Labcorp to scale its Ring, blood testing, glucose monitoring, environmental sensing and AI health-insights platform globally.
What happened
Indian health wearable company Ultrahuman raised $70 million from investors including Qualcomm Ventures and Labcorp to expand its body-focused human-computer
Key facts
- $70 million
- more than 90% accuracy
- 442 adults
- 227,860 nights
- 100 countries
Why this matters
Ultrahuman’s expansion creates partnership or acquisition opportunities across wearable technology, biomarker testing, glucose monitoring and personalized health-data platforms.
What to watch
- Launch of an integrated subscription combining Ring data, blood tests and glucose-monitoring insights.
- New retail listings with premium electronics, pharmacy, wellness, fitness or department-store partners outside India.
- Labcorp partnership details, including testing-market rollout, customer acquisition channels and revenue-sharing structure.
- Reported Ring sales, active subscribers, repeat test purchases and international revenue mix.
- Regulatory approvals, warnings or revised marketing language related to diagnostic and health-insight claims.
- Competitor responses from Oura, Apple, Samsung, Whoop or CGM companies, especially bundled metabolic-health offerings.
- Use the new capital to expand Ring distribution in North America, Europe and Gulf markets through selective premium retail and direct-to-consumer channels.
- Bundle the Ring with recurring blood-test and metabolic-health subscriptions to raise lifetime value and create a defensible health-data ecosystem.
- Pursue partnerships with laboratories, insurers, corporate-wellness providers, gyms and clinics to acquire customers at lower cost.
- Invest in AI health-insights features while tightening privacy, consent and medical-claims governance.
- Differentiate against Oura, Apple, Samsung and Whoop by positioning continuous biomarker intelligence rather than activity tracking alone.